Last reviewed · How we verify
intralesional rituximab
At a glance
| Generic name | intralesional rituximab |
|---|---|
| Also known as | Intraconjunctival rituximab; mabthera, anti-CD20 therapy |
| Sponsor | Andres J. M. Ferreri |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma (NA)
- RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT Lymphoma (NA)
- Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intralesional rituximab CI brief — competitive landscape report
- intralesional rituximab updates RSS · CI watch RSS
- Andres J. M. Ferreri portfolio CI